Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:TYP)
ASX:TYP
TYP Stock Chart & Stats
AU$0.03
>-AU$0.01(-2.56%)
At close: 4:00 PM EST
AU$0.03
>-AU$0.01(-2.56%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.05
Previous CloseN/A
Volume1.74M
Average Volume (3M)2.57M
Market Cap
AU$53.11M
Enterprise ValueAU$40.55M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,609,510,100
10 Day Avg. Volume1,495,343
30 Day Avg. Volume2,568,661
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tryptamine Therapeutics News
TYP FAQ
What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.03 and its highest was AU$0.05 in the past 12 months.
What is Tryptamine Therapeutics Limited’s market cap?
Tryptamine Therapeutics Limited’s market cap is AU$53.11M.
When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
Tryptamine Therapeutics Limited’s upcoming earnings report date is Feb 20, 2025 which is 298 days ago.
How were Tryptamine Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Tryptamine Therapeutics Limited overvalued?
According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Overvalued.
Does Tryptamine Therapeutics Limited pay dividends?
Tryptamine Therapeutics Limited does not currently pay dividends.
What is Tryptamine Therapeutics Limited’s EPS estimate?
Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics Limited have?
Tryptamine Therapeutics Limited has 1,609,510,100 shares outstanding.
What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:TYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tryptamine Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.66%
12-Months-Change
Fundamentals
Return on Equity
-94.13%
Trailing 12-Months
Asset Growth
-8.94%
Trailing 12-Months
Company Description
Tryptamine Therapeutics Limited
Exopharm Ltd is a biopharmaceutical company operating in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. Its products Plexaris and Exomere are developed using LEAP manufacturing process.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---